Regulation of brain reward by the endocannabinoid system: A critical review of behavioral studies in animals

Current Pharmaceutical Design

Volumn 20, Issue 13, 2014, Pages 2072-2088

  Vlachou, S ^b   Panagis, G ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

2 arachidonoylglycerol; Addiction; Anandamide; Cannabinoids; Conditioned place preference; Drug discrimination; Intracranial self stimulation; Self administration

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; ENDOCANNABINOID; CANNABINOID;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; BEHAVIORAL RESEARCH; BRAIN FUNCTION; MESENCEPHALON; MOUSE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; REWARD; SELF STIMULATION; ANIMAL; BRAIN; DRUG EFFECTS; DRUG SELF ADMINISTRATION; PHYSIOLOGY; SYNAPTIC TRANSMISSION;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CANNABINOIDS; ENDOCANNABINOIDS; MICE; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; REWARD; SELF ADMINISTRATION; SYNAPTIC TRANSMISSION;

EID: 84893343001     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990433     Document Type: Review

References (245)

1. Ramo DE, Liu H, Prochaska JJ. Reliability and validity of young adults' anonymous online reports of marijuana use and thoughts about use. Psychol Addict Behav 2011.
2. Schulden JD, Thomas YF, Compton WM. Substance abuse in the United States: findings from recent epidemiologic studies. Curr Psychiatry Rep 2009; 11: 353-9.
3. Haney M, Comer SD, Ward AS, Foltin RW, Fischman MW. Factors influencing marijuana self-administration by humans. Behav Pharmacol 1997; 8: 101-12.
4. Hart CL, Haney M, Vosburg SK, Comer SD, Foltin RW. Reinforcing effects of oral Delta9-THC in male marijuana smokers in a laboratory choice procedure. Psychopharmacology (Berl) 2005; 181: 237-43.
5. Justinova Z, Goldberg SR, Heishman SJ, Tanda G. Selfadministration of cannabinoids by experimental animals and human marijuana smokers. Pharmacol Biochem Behav 2005; 81: 285-99.
6. Solinas M, Yasar S, Goldberg SR. Endocannabinoid system involvement in brain reward processes related to drug abuse. Pharmacol Res 2007; 56: 393-405.
7. Panagis G, Vlachou S, Nomikos GG. Behavioral pharmacology of cannabinoids with a focus on preclinical models for studying reinforcing and dependence-producing properties. Curr Drug Abuse Rev 2008; 1: 350-74.
8. Bhattacharyya S, Atakan Z, Martin-Santos R, et al. Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of delta-9-tetrahydrocannabinol on midbrain and striatal function. Mol Psychiatry 2012.
9. Atakan Z, Bhattacharyya S, Allen P, et al. Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Delta9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers. Psychol Med 2012: 1-13.
10. Bhattacharyya S, Crippa JA, Allen P, et al. Induction of psychosis by Delta9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch Gen Psychiatry 2012; 69: 27-36.
11. Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010; 35: 764-74.
12. Fusar-Poli P, Allen P, Bhattacharyya S, et al. Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol. Int J Neuropsychopharmacol 2010; 13: 421-32.
13. Bhattacharyya S, Fusar-Poli P, Borgwardt S, et al. Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry 2009; 66: 442-51.
14. Fusar-Poli P, Crippa JA, Bhattacharyya S, et al. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 2009; 66: 95-105.
15. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3: 771-84.
16. Jonsson KO, Holt S, Fowler CJ. The endocannabinoid system: current pharmacological research and therapeutic possibilities. Basic Clin Pharmacol Toxicol 2006; 98: 124-34.
17. Mouslech Z, Valla V. Endocannabinoid system: An overview of its potential in current medical practice. Neuro Endocrinol Lett 2009; 30: 153-79.
18. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003; 4: 873-84.
19. Devane WA, Dysarz FA, 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34: 605-13.
20. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991; 11: 563-83.
21. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-4.
22. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-5.
23. Howlett AC. The cannabinoid receptors. Prostaglandins Other Lipid Mediat 2002; 68-69: 619-31.
24. Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990; 87: 1932-6.
25. Marsicano G, Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 1999; 11: 4213-25.
26. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998; 83: 393-411.
27. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science 2002; 296: 678-82.
28. Guzman M, Sanchez C, Galve-Roperh I. Control of the cell survival/ death decision by cannabinoids. J Mol Med (Berl) 2001; 78: 613-25.
29. Ehrhart J, Obregon D, Mori T, et al. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflammation 2005; 2: 29.
30. Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005; 310: 329-32.
31. Onaivi ES, Ishiguro H, Gong JP, et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 2006; 1074: 514-36.
32. Gong JP, Onaivi ES, Ishiguro H, et al. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 2006; 1071: 10-23.
33. Garcia-Gutierrez MS, Manzanares J. Overexpression of CB2 cannabinoid receptors decreased vulnerability to anxiety and impaired anxiolytic action of alprazolam in mice. J Psychopharmacol 2011; 25: 111-20.
34. Garcia-Gutierrez MS, Perez-Ortiz JM, Gutierrez-Adan A, Manzanares J. Depression-resistant endophenotype in mice overexpressing cannabinoid CB(2) receptors. Br J Pharmacol 2010; 160: 1773-84.
35. Begg M, Pacher P, Batkai S, et al. Evidence for novel cannabinoid receptors. Pharmacol Ther 2005; 106: 133-45.
36. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-9.
37. Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50: 83-90.
38. Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215: 89-97.
39. Zygmunt PM, Petersson J, Andersson DA, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999; 400: 452-7.
40. Jung KM, Mangieri R, Stapleton C, et al. Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Mol Pharmacol 2005; 68: 1196-202.
41. Hanus L, Abu-Lafi S, Fride E, et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 2001; 98: 3662-5.
42. Porter AC, Sauer JM, Knierman MD, et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002; 301: 1020-4.
43. Melis M, Muntoni AL, Pistis M. Endocannabinoids and the processing of value-related signals. Front Pharmacol 2012; 3: 7.
44. Oleson EB, Beckert MV, Morra JT, et al. Endocannabinoids shape accumbal encoding of cue-motivated behavior via CB1 receptor activation in the ventral tegmentum. Neuron 2012; 73: 360-73.
45. Di Marzo V. Endocannabinoids: synthesis and degradation. Rev Physiol Biochem Pharmacol 2008; 160: 1-24.
46. Alger BE, Kim J. Supply and demand for endocannabinoids. Trends Neurosci 2011; 34: 304-15.
47. Di Marzo V, Melck D, Bisogno T, De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 1998; 21: 521-8.
48. Jiang W, Zhang Y, Xiao L, et al. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic-and antidepressant-like effects. J Clin Invest 2005; 115: 3104-16.
49. Fowler CJ, Rojo ML, Rodriguez-Gaztelumendi A. Modulation of the endocannabinoid system: neuroprotection or neurotoxicity? Exp Neurol 2010; 224: 37-47.
50. Pertwee RG. Cannabinoid receptors and pain. Prog Neurobiol 2001; 63: 569-611.
51. Bermudez-Silva FJ, Viveros MP, McPartland JM, Rodriguez de Fonseca F. The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning? Pharmacol Biochem Behav 2010; 95: 375-82.
52. Lutz B. Endocannabinoid signals in the control of emotion. Curr Opin Pharmacol 2009; 9: 46-52.
53. Viveros MP, Marco EM, Llorente R, Lopez-Gallardo M. Endocannabinoid system and synaptic plasticity: implications for emotional responses. Neural Plast 2007; 2007: 52908.
54. Viveros MP, Marco EM, File SE. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 2005; 81: 331-42.
55. Hill MN, McLaughlin RJ, Bingham B, et al. Endogenous cannabinoid signaling is essential for stress adaptation. Proc Natl Acad Sci USA 2010; 107: 9406-11.
56. Hampson RE, Deadwyler SA. Cannabinoids, hippocampal function and memory. Life Sci 1999; 65: 715-23.
57. Fernandez-Ruiz J. The endocannabinoid system as a target for the treatment of motor dysfunction. Br J Pharmacol 2009; 156: 1029-40.
58. El Manira A, Kyriakatos A. The role of endocannabinoid signaling in motor control. Physiology (Bethesda) 2010; 25: 230-8.
59. Baker D, Pryce G, Croxford JL, et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 2001; 15: 300-2.
60. Pazos MR, Sagredo O, Fernandez-Ruiz J. The endocannabinoid system in Huntington's disease. Curr Pharm Des 2008; 14: 2317-25.
61. Pisani V, Madeo G, Tassone A, et al. Homeostatic changes of the endocannabinoid system in Parkinson's disease. Mov Disord 2011; 26: 216-22.
62. Serrano A, Parsons LH. Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. Pharmacol Ther 2011; 132: 215-41.
63. Ashton CH, Moore PB. Endocannabinoid system dysfunction in mood and related disorders. Acta Psychiatr Scand 2011; 124: 250-61.
64. Bossong MG, Niesink RJ. Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabisinduced schizophrenia. Prog Neurobiol 2010; 92: 370-85.
65. Pertwee RG, Howlett AC, Abood ME, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). Pharmacol Rev 2010; 62: 588-631.
66. Pertwee RG. Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol 2008; 13: 147-59.
67. Pertwee RG. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 2005; 76: 1307-24.
68. Ross RA, Brockie HC, Stevenson LA, et al. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol 1999; 126: 665-72.
69. Pertwee RG. Pharmacology of cannabinoid receptor ligands. Curr Med Chem 1999; 6: 635-64.
70. Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 2007; 150: 613-23.
71. Ortega-Gutierrez S. Therapeutic perspectives of inhibitors of endocannabinoid degradation. Curr Drug Targets CNS Neurol Disord 2005; 4: 697-707.
72. Cravatt BF, Lichtman AH. Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr Opin Chem Biol 2003; 7: 469-75.
73. Di Marzo V, De Petrocellis L, Bisogno T. The biosynthesis, fate and pharmacological properties of endocannabinoids. Handb Exp Pharmacol 2005: 147-85.
74. Kunos G, Batkai S. Novel physiologic functions of endocannabinoids as revealed through the use of mutant mice. Neurochem Res 2001; 26: 1015-21.
75. Valverde O, Karsak M, Zimmer A. Analysis of the endocannabinoid system by using CB1 cannabinoid receptor knockout mice. Handb Exp Pharmacol 2005: 117-45.
76. Cravatt BF, Demarest K, Patricelli MP, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 2001; 98: 9371-6.
77. Panlilio LV, Justinova Z, Goldberg SR. Animal models of cannabinoid reward. Br J Pharmacol. 2010; 160: 499-510.
78. Kornetsky C. Brain-stimulation reward: a model for the neuronal bases for drug-induced euphoria. NIDA Res Monogr 1985; 62: 30-50.
79. Wise RA. Addictive drugs and brain stimulation reward. Annu Rev Neurosci 1996; 19: 319-40.
80. Vlachou S, Markou A. The use of the intracranial self-stimulation in drug abuse research: Addictive drugs and the neurobiology of reward and motivation. In: Olmstead MC, ed.eds., Animal models of drug addiction. Humana Press and Springer Science: New York 2011; pp. 3-56.
81. Markou A, Koob GF. Intracranial self-stimulation thresholds as a measure of reward. IRL Press: Oxford 1993.
82. Gardner EL. What we have learned about addiction from animal models of drug self-administration. Am J Addict. 2000; 9: 285-313.
83. Bardo MT, Bevins RA. Conditioned place preference: what does it add to our preclinical understanding of drug reward? Psychopharmacology (Berl) 2000; 153: 31-43.
84. Sanchis-Segura C, Spanagel R. Behavioural assessment of drug reinforcement and addictive features in rodents: an overview. Addict Biol 2006; 11: 2-38.
85. Stolerman IP, Rasul F, Shine PJ. Trends in drug discrimination research analysed with a cross-indexed bibliography 1984-1987. Psychopharmacology (Berl) 1989; 98: 1-19.
86. Katz JL, Goldberg SR. Preclinical assessment of abuse liability of drugs. Agents Actions 1988; 23: 18-26.
87. Balster RL. Drug abuse potential evaluation in animals. Br J Addict 1991; 86: 1549-58.
88. Gardner EL, Vorel S.R. Facilitation of brain stimulation reward by delta-9-tetrahydrocannabinol is mediated by an endogenous opioid mechanism. Advances in Biosciences 1989; 75: 4.
89. Gardner EL, Lowinson JH. Marijuana's interaction with brain reward systems: update 1991. Pharmacol Biochem Behav 1991; 40: 571-80.
90. Gardner EL, Paredes W, Smith D, et al. Facilitation of brain stimulation reward by delta 9-tetrahydrocannabinol. Psychopharmacology (Berl) 1988; 96: 142-4.
91. Gardner EL, Vorel SR. Cannabinoid transmission and rewardrelated events. Neurobiol Dis 1998; 5: 502-33.
92. Lepore M, Liu X, Savage V, Matalon D, Gardner EL. Genetic differences in delta 9-tetrahydrocannabinol-induced facilitation of brain stimulation reward as measured by a rate-frequency curveshift electrical brain stimulation paradigm in three different rat strains. Life Sci 1996; 58: PL365-72.
93. Kucharski LT, Williams JE, Kornetsky C. The effects of levonantradol on rewarding brain stimulation thresholds in the rat. Pharmacol Biochem Behav 1983; 19: 149-51.
94. Stark P, Dews PB. Cannabinoids. I. Behavioral effects. J Pharmacol Exp Ther 1980; 214: 124-30.
95. Vlachou S, Nomikos GG, Stephens DN, Panagis G. Lack of evidence for appetitive effects of Delta 9-tetrahydrocannabinol in the intracranial self-stimulation and conditioned place preference procedures in rodents. Behav Pharmacol 2007; 18: 311-9.
96. Fokos S, Panagis G. Effects of delta9-tetrahydrocannabinol on reward and anxiety in rats exposed to chronic unpredictable stress. J Psychopharmacol. 2010; 24: 767-77. Epub 2009 Apr 30.
97. Corcoran ME, Amit Z. Reluctance of rats to drink hashish suspensions: free-choice and forced consumption, and the effects of hypothalamic stimulation. Psychopharmacologia. 1974; 35: 129-47.
98. Mansbach RS, Nicholson KL, Martin BR, Balster RL. Failure of Delta(9)-tetrahydrocannabinol and CP 55,940 to maintain intravenous self-administration under a fixed-interval schedule in rhesus monkeys. Behav Pharmacol. 1994; 5: 219-25.
99. Harris RT, Waters W, McLendon D. Evaluation of reinforcing capability of delta-9-tetrahydrocannabinol in rhesus monkeys. Psychopharmacologia 1974; 37: 23-9.
100. van Ree JM, Slangen JL, de Wied D. Intravenous selfadministration of drugs in rats. J Pharmacol Exp Ther 1978; 204: 547-57.
101. Young AM, Katz JL, Woods JH. Behavioral effects of levonantradol and nantradol in the rhesus monkey. J Clin Pharmacol. 1981; 21: 348S-360S.
102. Deneau G, Kaymakcalan S. Physiological and psychological dependence to synthetic _9-tetrahydrocannabinol (THC) in rhesus monkeys. The Pharmacologist 1971; 13: 246-8.
103. Kaymakcalan S. Tolerance to and dependence on cannabis. Bull Narc 1973; 25: 39-47.
104. de la Garza R, Johanson CE. The effects of food deprivation on the self-administration of psychoactive drugs. Drug Alcohol Depend 1987; 19: 17-27.
105. Takahashi RN, Singer G. Effects of body weight levels on cannabis self-injection Self-administration of delta 9-tetrahydrocannabinol by rats. Pharmacol Biochem Behav 1980; 13: 877-81.
106. Takahashi RN, Singer G. Self-administration of delta 9-tetrahydrocannabinol by rats. Pharmacol Biochem Behav 1979; 11: 737-40.
107. Pickens RTT, Muchow DC. Cannabis and phencyclidine selfadministration by animals. In: Goldfarb L, Hoffmeister F. Eds, Psychic dependence [Bayer Symposium IV]. Berlin Heidelberg New York, Springer. 1973; pp. 78-86.
108. Tanda G, Munzar P, Goldberg SR. Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci 2000; 3: 1073-4.
109. Justinova Z, Tanda G, Redhi GH, Goldberg SR. Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology (Berl) 2003; 169: 135-40.
110. Justinova Z, Munzar P, Panlilio LV, et al. Blockade of THCseeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant. Neuropsychopharmacology 2008; 33: 2870-7.
111. Braida D, Iosue S, Pegorini S, Sala M. Delta9-tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats. Eur J Pharmacol 2004; 506: 63-9.
112. Zangen A, Solinas M, Ikemoto S, Goldberg SR, Wise RA. Two brain sites for cannabinoid reward. J Neurosci 2006; 26: 4901-7.
113. Murray JE, Bevins RA. Cannabinoid conditioned reward and aversion: behavioral and neural processes. ACS Chem Neurosci 2010; 1: 265-278.
114. Lepore M, Vorel SR, Lowinson J, Gardner EL. Conditioned place preference induced by delta 9-tetrahydrocannabinol: comparison with cocaine, morphine, and food reward. Life Sci 1995; 56: 2073-80.
115. Parker LA, Gillies T. THC-induced place and taste aversions in Lewis and Sprague-Dawley rats. Behav Neurosci 1995; 109: 71-8.
116. Cheer JF, Kendall DA, Marsden CA. Cannabinoid receptors and reward in the rat: a conditioned place preference study. Psychopharmacology (Berl) 2000; 151: 25-30.
117. Mallet PE, Beninger RJ. Delta9-tetrahydrocannabinol, but not the endogenous cannabinoid receptor ligand anandamide, produces conditioned place avoidance. Life Sci 1998; 62: 2431-9.
118. Elsmore TF, Fletcher GV. Delta 9-tetrahydrocannabinol: aversive effects in rat at high doses. Science 1972; 175: 911-2.
119. Hutcheson DM, Tzavara ET, Smadja C, et al. Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol. Br J Pharmacol 1998; 125: 1567-77.
120. Robinson L, Hinder L, Pertwee RG, Riedel G. Effects of delta9-THC and WIN-55,212-2 on place preference in the water maze in rats. Psychopharmacology (Berl) 2003; 166: 40-50.
121. Sanudo-Pena MC, Tsou K, Delay ER, Hohman AG, Force M, Walker JM. Endogenous cannabinoids as an aversive or counterrewarding system in the rat. Neurosci Lett 1997; 223: 125-8.
122. Zimmer A, Valjent E, Konig M, et al. Absence of delta-9-tetrahydrocannabinol dysphoric effects in dynorphin-deficient mice. J Neurosci 2001; 21: 9499-505.
123. Le Foll B, Wiggins M, Goldberg SR. Nicotine pre-exposure does not potentiate the locomotor or rewarding effects of Delta-9-tetrahydrocannabinol in rats. Behav Pharmacol 2006; 17: 195-9.
124. Valjent E, Maldonado R. A behavioural model to reveal place preference to delta 9-tetrahydrocannabinol in mice. Psychopharmacology (Berl). 2000; 147: 436-8.
125. Soria G, Castane A, Berrendero F, et al. Adenosine A2A receptors are involved in physical dependence and place conditioning induced by THC. Eur J Neurosci 2004; 20: 2203-13.
126. De Vry J, Jentzsch KR. Intrinsic activity estimation of cannabinoid CB1 receptor ligands in a drug discrimination paradigm. Behav Pharmacol 2003; 14: 471-6.
127. Balster RL, Prescott WR. Delta 9-tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. Neurosci Biobehav Rev 1992; 16: 55-62.
128. Barrett RL, Wiley JL, Balster RL, Martin BR. Pharmacological specificity of delta 9-tetrahydrocannabinol discrimination in rats. Psychopharmacology (Berl) 1995; 118: 419-24.
129. Wiley JL, Barrett RL, Britt DT, Balster RL, Martin BR. Discriminative stimulus effects of delta 9-tetrahydrocannabinol and delta 9-11-tetrahydrocannabinol in rats and rhesus monkeys. Neuropharmacology 1993; 32: 359-65.
130. De Vry J, Jentzsch KR. Discriminative stimulus effects of the structurally novel cannabinoid CB1/CB2 receptor partial agonist BAY 59-3074 in the rat. Eur J Pharmacol 2004; 505: 127-33.
131. Gold LH, Balster RL, Barrett RL, Britt DT, Martin BR. A comparison of the discriminative stimulus properties of delta 9-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys. J Pharmacol Exp Ther 1992; 262: 479-86.
132. Wiley JL, Barrett RL, Balster RL, Martin BR. Tolerance to the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol. Behav Pharmacol 1993; 4: 581-5.
133. McMahon LR. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol. J Pharmacol Exp Ther 2006; 319: 1211-8.
134. Antoniou K, Galanopoulos A, Vlachou S, et al. Behavioral pharmacological properties of a novel cannabinoid 1',1'-dithiolane delta8-THC analog, AMG-3. Behav Pharmacol 2005; 16: 499-510.
135. Vlachou S, Nomikos GG, Panagis G. WIN 55,212-2 decreases the reinforcing actions of cocaine through CB1 cannabinoid receptor stimulation. Behav Brain Res 2003; 141: 215-22.
136. Vlachou S, Nomikos GG, Panagis G. CB1 cannabinoid receptor agonists increase intracranial self-stimulation thresholds in the rat. Psychopharmacology (Berl) 2005; 179: 498-508.
137. Vlachou S, Nomikos GG, Panagis G. Effects of endocannabinoid neurotransmission modulators on brain stimulation reward. Psychopharmacology (Berl) 2006; 188: 293-305.
138. Arnold JC, Hunt GE, McGregor IS. Effects of the cannabinoid receptor agonist CP 55,940 and the cannabinoid receptor antagonist SR 141716 on intracranial self-stimulation in Lewis rats. Life Sci 2001; 70: 97-108.
139. Fattore L, Cossu G, Martellotta CM, Fratta W. Intravenous selfadministration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats. Psychopharmacology (Berl). 2001; 156: 410-6.
140. Fadda P, Scherma M, Spano MS, et al. Cannabinoid selfadministration increases dopamine release in the nucleus accumbens. Neuroreport 2006; 17: 1629-32.
141. Fattore L, Vigano D, Fadda P, Rubino T, Fratta W, Parolaro D. Bidirectional regulation of mu-opioid and CB1-cannabinoid receptor in rats self-administering heroin or WIN 55,212-2. Eur J Neurosci 2007; 25: 2191-200.
142. Lecca D, Cacciapaglia F, Valentini V, Di Chiara G. Monitoring extracellular dopamine in the rat nucleus accumbens shell and core during acquisition and maintenance of intravenous WIN 55,212-2 self-administration. Psychopharmacology (Berl) 2006; 188: 63-74.
143. Martellotta MC, Cossu G, Fattore L, Gessa GL, Fratta W. Selfadministration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice. Neuroscience 1998; 85: 327-30.
144. Navarro M, Carrera MR, Fratta W, et al. Functional interaction between opioid and cannabinoid receptors in drug selfadministration. J Neurosci. 2001; 21: 5344-50.
145. Braida D, Pozzi M, Parolaro D, Sala M. Intracerebral selfadministration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system. Eur J Pharmacol. 2001; 413: 227-34.
146. McGregor IS, Issakidis CN, Prior G. Aversive effects of the synthetic cannabinoid CP 55,940 in rats. Pharmacol Biochem Behav 1996; 53: 657-64.
147. Braida D, Pozzi M, Cavallini R, Sala M. Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system. Neuroscience 2001; 104: 923-6.
148. Polissidis A, Chouliara O, Galanopoulos A, Marselos M, Papadopoulou-Daifoti Z, Antoniou K. Behavioural and dopaminergic alterations induced by a low dose of WIN 55,212-2 in a conditioned place preference procedure. Life Sci 2009; 85: 248-54.
149. Chaperon F, Soubrie P, Puech AJ, Thiebot MH. Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology (Berl) 1998; 135: 324-32.
150. Castane A, Maldonado R, Valverde O. Role of different brain structures in the behavioural expression of WIN 55,212-2 withdrawal in mice. Br J Pharmacol 2004; 142: 1309-17.
151. Wiley JL, Barrett RL, Lowe J, Balster RL, Martin BR. Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats. Neuropharmacology 1995; 34: 669-76.
152. Jarbe TU, Lamb RJ, Lin S, Makriyannis A. (R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide. Psychopharmacology (Berl) 2001; 156: 369-80.
153. Jarbe TU, Liu Q, Makriyannis A. Antagonism of discriminative stimulus effects of delta(9)-THC and (R)-methanandamide in rats. Psychopharmacology (Berl) 2006; 184: 36-45.
154. Mansbach RS, Rovetti CC, Winston EN, Lowe JA, 3rd. Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats. Psychopharmacology (Berl) 1996; 124: 315-22.
155. Perio A, Rinaldi-Carmona M, Maruani J, Barth F, Le Fur G, Soubrie P. Central mediation of the cannabinoid cue: activity of a selective CB1 antagonist, SR 141716A. Behav Pharmacol 1996; 7: 65-71.
156. Martin BR, Kallman MJ, Kaempf GF, Harris LS, Dewey WL, Razdan RK. Pharmacological potency of R-and S-3'-hydroxy-delta 9-tetrahydrocannabinol: additional structural requirement for cannabinoid activity. Pharmacol Biochem Behav 1984; 21: 61-5.
157. Lile JA, Kelly TH, Hays LR. Separate and combined effects of the cannabinoid agonists nabilone and Delta(9)-THC in humans discriminating Delta(9)-THC. Drug Alcohol Depend 2011; 116: 86-92.
158. Browne RG, Weissman A. Discriminative stimulus properties of delta 9-tetrahydrocannabinol: mechanistic studies. J Clin Pharmacol 1981; 21: 227S-234S.
159. Jarbe TU, Lamb RJ. Effects of lithium dose (UCS) on the acquisition and extinction of a discriminated morphine aversion: tests with morphine and delta9-THC. Behav Pharmacol 1999; 10: 349-58.
160. Jarbe TU, Lamb RJ, Makriyannis A, Lin S, Goutopoulos A. Delta9-THC training dose as a determinant for (R)-methanandamide generalization in rats. Psychopharmacology (Berl) 1998; 140: 519-22.
161. Mokler DJ, Nelson BD, Harris LS, Rosecrans JA. The role of benzodiazepine receptors in the discriminative stimulus properties of delta-9-tetrahydrocannabinol. Life Sci 1986; 38: 1581-9.
162. Wiley JL, Martin BR. Effects of SR141716A on diazepam substitution for delta9-tetrahydrocannabinol in rat drug discrimination. Pharmacol Biochem Behav 1999; 64: 519-22.
163. Solinas M, Zangen A, Thiriet N, Goldberg SR. Beta-endorphin elevations in the ventral tegmental area regulate the discriminative effects of Delta-9-tetrahydrocannabinol. Eur J Neurosci 2004; 19: 3183-92.
164. Solinas M, Goldberg SR. Involvement of mu-, delta-and kappaopioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats. Psychopharmacology (Berl) 2005; 179: 804-12.
165. Solinas M, Scherma M, Tanda G, Wertheim CE, Fratta W, Goldberg SR. Nicotinic facilitation of delta9-tetrahydrocannabinol discrimination involves endogenous anandamide. J Pharmacol Exp Ther 2007; 321: 1127-34.
166. Lile JA, Kelly TH, Hays LR. Separate and combined effects of the GABA reuptake inhibitor tiagabine and Delta9-THC in humans discriminating Delta9-THC. Drug Alcohol Depend 2012; 122: 61-9.
167. Pierce RC, Kumaresan V. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev 2006; 30: 215-38.
168. Viveros MP, Marco EM, File SE. Nicotine and cannabinoids: parallels, contrasts and interactions. Neurosci Biobehav Rev 2006; 30: 1161-81.
169. Trigo JM, Martin-Garcia E, Berrendero F, Robledo P, Maldonado R. The endogenous opioid system: a common substrate in drug addiction. Drug Alcohol Depend 2010; 108: 183-94.
170. Tuesta LM, Fowler CD, Kenny PJ. Recent advances in understanding nicotinic receptor signaling mechanisms that regulate drug selfadministration behavior. Biochem Pharmacol 2011; 82: 984-95.
171. Le Merrer J, Befort K, Gardon O, et al. Protracted abstinence from distinct drugs of abuse shows regulation of a common gene network. Addict Biol 2012; 17: 1-12.
172. Pava MJ, Woodward JJ. A review of the interactions between alcohol and the endocannabinoid system: implications for alcohol dependence and future directions for research. Alcohol 2012; 46: 185-204.
173. Justinova Z, Solinas M, Tanda G, Redhi GH, Goldberg SR. The endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide are intravenously self-administered by squirrel monkeys. J Neurosci 2005; 25: 5645-50.
174. Shaham Y, Shalev U, Lu L, De Wit H, Stewart J. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl) 2003; 168: 3-20.
175. Deroche-Gamonet V, Le Moal M, Piazza PV, Soubrie P. SR141716, a CB1 receptor antagonist, decreases the sensitivity to the reinforcing effects of electrical brain stimulation in rats. Psychopharmacology (Berl) 2001; 157: 254-9.
176. Bouaboula M, Perrachon S, Milligan L, et al. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 1997; 272: 22330-9.
177. Landsman RS, Burkey TH, Consroe P, Roeske WR, Yamamura HI. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur J Pharmacol 1997; 334: R1-2.
178. Xi ZX, Spiller K, Pak AC, et al. Cannabinoid CB1 receptor antagonists attenuate cocaine's rewarding effects: experiments with self-administration and brain-stimulation reward in rats. Neuropsychopharmacology 2008; 33: 1735-45.
179. Burch J, McKenna C, Palmer S, et al. Rimonabant for the treatment of overweight and obese people. Health Technol Assess 2009; 13 Suppl 3: 13-22.
180. Christopoulou FD, Kiortsis DN. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity. J Clin Pharm Ther 2011; 36: 10-8.
181. Forslund T, Raaschou P, Hjemdahl P, Krakau I, Wettermark B. Usage, risk, and benefit of weight-loss drugs in primary care. J Obes 2011; 2011: 459263.
182. Leite CE, Mocelin CA, Petersen GO, Leal MB, Thiesen FV. Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity. Pharmacol Rep 2009; 61: 217-24.
183. Davis SN, Perkins JM. Role of the endocannabinoid system in management of patients with type 2 diabetes mellitus and cardiovascular risk factors. Endocr Pract 2007; 13: 790-804.
184. Maldonado R, Valverde O, Berrendero F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 2006; 29: 225-32.
185. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a metaanalysis of randomised trials. Lancet 2007; 370: 1706-13.
186. Buggy Y, Cornelius V, Wilton L, Shakir SA. Risk of depressive episodes with rimonabant: a before and after modified prescription event monitoring study conducted in England. Drug Saf 2011; 34: 501-9.
187. de Mattos Viana B, Prais HA, Daker MV. Melancholic features related to rimonabant. Gen Hosp Psychiatry 2009; 31: 583-5.
188. Horder J, Browning M, Di Simplicio M, Cowen PJ, Harmer CJ. Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing. J Psychopharmacol 2012; 26: 125-32.
189. Kelly DL, Gorelick DA, Conley RR, et al. Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol 2011; 31: 86-91.
190. Moreira FA, Crippa JA. The psychiatric side-effects of rimonabant. Rev Bras Psiquiatr 2009; 31: 145-53.
191. Nathan PJ, O'Neill BV, Napolitano A, Bullmore ET. Neuropsychiatric adverse effects of centrally acting antiobesity drugs. CNS Neurosci Ther 2011; 17: 490-505.
192. Le Foll B, Gorelick DA, Goldberg SR. The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl) 2009; 205: 171-4.
193. Wu YK, Yeh CF, Ly TW, Hung MS. A new perspective of cannabinoid 1 receptor antagonists: approaches toward peripheral CB1R blockers without crossing the blood-brain barrier. Curr Top Med Chem 2011; 11: 1421-9.
194. Randall PA, Vemuri VK, Segovia KN, et al. The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and foodreinforced behavior. Pharmacol Biochem Behav 2010; 97: 179-84.
195. Fattore L, Cossu G, Spano MS, et al. Cannabinoids and reward: interactions with the opioid system. Crit Rev Neurobiol 2004; 16: 147-58.
196. Wiskerke J, Pattij T, Schoffelmeer AN, De Vries TJ. The role of CB1 receptors in psychostimulant addiction. Addict Biol 2008; 13: 225-38.
197. Ledent C, Valverde O, Cossu G, et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999; 283: 401-4.
198. Cossu G, Ledent C, Fattore L, et al. Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav Brain Res 2001; 118: 61-5.
199. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. Eur J Neurosci 2000; 12: 4038-46.
200. Rice OV, Gordon N, Gifford AN. Conditioned place preference to morphine in cannabinoid CB1 receptor knockout mice. Brain Res 2002; 945: 135-8.
201. Soria G, Mendizabal V, Tourino C, et al. Lack of CB1 cannabinoid receptor impairs cocaine self-administration. Neuropsychopharmacology 2005; 30: 1670-80.
202. Castane A, Valjent E, Ledent C, Parmentier M, Maldonado R, Valverde O. Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology 2002; 43: 857-67.
203. Metrik J, Rohsenow DJ, Monti PM, et al. Effectiveness of a marijuana expectancy manipulation: Piloting the balanced-placebo design for marijuana. Exp Clin Psychopharmacol 2009; 17: 217-25.
204. Houchi H, Babovic D, Pierrefiche O, Ledent C, Daoust M, Naassila M. CB1 receptor knockout mice display reduced ethanol-induced conditioned place preference and increased striatal dopamine D2 receptors. Neuropsychopharmacology 2005; 30: 339-49.
205. Thanos PK, Dimitrakakis ES, Rice O, Gifford A, Volkow ND. Ethanol self-administration and ethanol conditioned place preference are reduced in mice lacking cannabinoid CB1 receptors. Behav Brain Res 2005; 164: 206-13.
206. Wang L, Liu J, Harvey-White J, Zimmer A, Kunos G. Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc Natl Acad Sci USA 2003; 100: 1393-8.
207. Kunos G. Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system? Am J Med 2007; 120: S18-24; discussion S24.
208. Janero DR, Makriyannis A. Targeted modulators of the endogenous cannabinoid system: future medications to treat addiction disorders and obesity. Curr Psychiatry Rep 2007; 9: 365-73.
209. Dipatrizio NV, Simansky KJ. Inhibiting parabrachial fatty acid amide hydrolase activity selectively increases the intake of palatable food via cannabinoid CB1 receptors. Am J Physiol Regul Integr Comp Physiol 2008; 295: R1409-14.
210. DiPatrizio NV, Simansky KJ. Activating parabrachial cannabinoid CB1 receptors selectively stimulates feeding of palatable foods in rats. J Neurosci 2008; 28: 9702-9.
211. Bello NT, Coughlin JW, Redgrave GW, et al. Dietary conditions and highly palatable food access alter rat cannabinoid receptor expression and binding density. Physiol Behav 2012; 105: 720-6.
212. Yoshida R, Ohkuri T, Jyotaki M, et al. Endocannabinoids selectively enhance sweet taste. Proc Natl Acad Sci USA 2010; 107: 935-9.
213. Economidou D, Mattioli L, Cifani C, et al. Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol selfadministration and ethanol-seeking behaviour in rats. Psychopharmacology (Berl) 2006; 183: 394-403.
214. Jarrett MM, Scantlebury J, Parker LA. Effect of delta9-tetrahydrocannabinol on quinine palatability and AM251 on sucrose and quinine palatability using the taste reactivity test. Physiol Behav 2007; 90: 425-30.
215. De Luca MA, Solinas M, Bimpisidis Z, Goldberg SR, Di Chiara G. Cannabinoid facilitation of behavioral and biochemical hedonic taste responses. Neuropharmacology 2012; 63: 161-8.
216. Brand T, Spanagel R, Schneider M. Decreased reward sensitivity in rats from the Fischer344 strain compared to Wistar rats is paralleled by differences in endocannabinoid signaling. PLoS One 2012; 7: e31169.
217. Jo YH, Chen YJ, Chua SC, Jr., Talmage DA, Role LW. Integration of endocannabinoid and leptin signaling in an appetite-related neural circuit. Neuron 2005; 48: 1055-66.
218. Sanchis-Segura C, Cline BH, Marsicano G, Lutz B, Spanagel R. Reduced sensitivity to reward in CB1 knockout mice. Psychopharmacology (Berl) 2004; 176: 223-32.
219. Ward SJ, Dykstra LA. The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940). Behav Pharmacol 2005; 16: 381-8.
220. Ishiguro H, Iwasaki S, Teasenfitz L, et al. Involvement of cannabinoid CB2 receptor in alcohol preference in mice and alcoholism in humans. Pharmacogenomics J 2007; 7: 380-5.
221. Onaivi ES, Ishiguro H, Gong JP, et al. Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS One 2008; 3: e1640.
222. Xi ZX, Peng XQ, Li X, et al. Brain cannabinoid CB(2) receptors modulate cocaine's actions in mice. Nat Neurosci 2011; 14: 1160-6.
223. Aracil-Fernandez A, Trigo JM, Garcia-Gutierrez MS, et al. Decreased Cocaine Motor Sensitization and Self-Administration in Mice Overexpressing Cannabinoid CB(2) Receptors. Neuropsychopharmacology 2012; 37: 1749-63.
224. Adamczyk P, Miszkiel J, McCreary AC, Filip M, Papp M, Przegalinski E. The effects of cannabinoid CB1, CB2 and vanilloid TRPV1 receptor antagonists on cocaine addictive behavior in rats. Brain Res 2012; 1444: 45-54.
225. Gamaleddin I, Zvonok A, Makriyannis A, Goldberg SR, Le Foll B. Effects of a selective cannabinoid CB2 agonist and antagonist on intravenous nicotine self administration and reinstatement of nicotine seeking. PLoS One 2012; 7: e29900.
226. Solinas M, Justinova Z, Goldberg SR, Tanda G. Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. J Neurochem 2006; 98: 408-19.
227. Solinas M, Goldberg SR, Piomelli D. The endocannabinoid system in brain reward processes. Br J Pharmacol 2008; 154: 369-83.
228. Lupica CR, Riegel AC, Hoffman AF. Marijuana and cannabinoid regulation of brain reward circuits. Br J Pharmacol 2004; 143: 227-34.
229. Justinova Z, Yasar S, Redhi GH, Goldberg SR. The endogenous cannabinoid 2-arachidonoylglycerol is intravenously selfadministered by squirrel monkeys. J Neurosci 2011; 31: 7043-8.
230. Justinova Z, Mangieri RA, Bortolato M, et al. Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol Psychiatry 2008; 64: 930-7.
231. Scherma M, Medalie J, Fratta W, et al. The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology 2008; 54: 129-40.
232. Hao S, Avraham Y, Mechoulam R, Berry EM. Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur J Pharmacol 2000; 392: 147-56.
233. Higgs S, Williams CM, Kirkham TC. Cannabinoid influences on palatability: microstructural analysis of sucrose drinking after delta(9)-tetrahydrocannabinol, anandamide, 2-arachidonoyl glycerol and SR141716. Psychopharmacology (Berl) 2003; 165: 370-7.
234. Mahler SV, Smith KS, Berridge KC. Endocannabinoid hedonic hotspot for sensory pleasure: anandamide in nucleus accumbens shell enhances 'liking' of a sweet reward. Neuropsychopharmacology 2007; 32: 2267-78.
235. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002; 136: 550-7.
236. Burkey RT, Nation JR. (R)-methanandamide, but not anandamide, substitutes for delta 9-THC in a drug-discrimination procedure. Exp Clin Psychopharmacol 1997; 5: 195-202.
237. Wiley JL, Golden KM, Ryan WJ, Balster RL, Razdan RK, Martin BR. Evaluation of cannabimimetic discriminative stimulus effects of anandamide and methylated fluoroanandamide in rhesus monkeys. Pharmacol Biochem Behav 1997; 58: 1139-43.
238. Alici T, Appel JB. Increasing the selectivity of the discriminative stimulus effects of delta 9-tetrahydrocannabinol: complete substitution with methanandamide. Pharmacol Biochem Behav 2004; 79: 431-7.
239. Jarbe TU, Lamb RJ, Liu Q, Makriyannis A. Discriminative stimulus functions of AM-1346, a CB1R selective anandamide analog in rats trained with Delta9-THC or (R)-methanandamide (AM-356). Psychopharmacology (Berl) 2006; 188: 315-23.
240. Wiley JL, LaVecchia KL, Karp NE, et al. A comparison of the discriminative stimulus effects of delta(9)-tetrahydrocannabinol and O-1812, a potent and metabolically stable anandamide analog, in rats. Exp Clin Psychopharmacol 2004; 12: 173-9.
241. Solinas M, Tanda G, Justinova Z, et al. The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. J Pharmacol Exp Ther 2007; 321: 370-80.
242. Bortolato M, Campolongo P, Mangieri RA, et al. Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology 2006; 31: 2652-9.
243. Gobbi G, Bambico FR, Mangieri R, et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 2005; 102: 18620-5.
244. Solinas M, Panlilio LV, Tanda G, Makriyannis A, Matthews SA, Goldberg SR. Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats. Neuropsychopharmacology 2005; 30: 2046-57.
245. Merritt LL, Martin BR, Walters C, Lichtman AH, Damaj MI. The endogenous cannabinoid system modulates nicotine reward and dependence. J Pharmacol Exp Ther 2008; 326: 483-92.